Highlights:
-
Discipline and diligence around quality of revenue realised significant increase in Gross Margin.
-
Quarterly Gross Profit increased from $2.4m to $3.8m yoy.
-
3QFY23 Product Sales (unaudited) increased 60% yoy to US$5.0m however, decreased 11% qoq due to transitioning DME customer base.
-
Cash on hand for 30 September was US$12.4m.
Sydney Australia Monday, 23 October 2023: Next Science Limited (ASX: NXS) (Next Science), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, is pleased to provide an update on its activities for the quarter ended 30 September 2023.
For more information, download the attached PDF.
Download this document
